SEC Form 4 · accession 0001179110-17-013378
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Santosh Vetticaden
Officer — SVP, Chief Medical Officer ***
Period of report
Oct 16, 2017
Accepted (ET)
Oct 18, 2017 · 6:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $5.06 | Oct 16, 2017 | A | 109,343 | A | — | Oct 16, 2027 | Common Stock | 109,343 | 109,343 | D |
| Restricted Stock UnitsF2,F3 | — | Oct 16, 2017 | A | 53,325 | A | — | — | Common Stock | 53,325 | 53,325 | D |
Explanation of responses
- F1Exercisable with respect to 25% of the underlying shares on October 16, 2018, and in 36 equal monthly installments thereafter, such that the stock options will be fully vested and exercisable on October 16, 2021.
- F2Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
- F3These restricted stock units are scheduled to vest 25% on October 16, 2018, 25% on October 16, 2019, 25% on October 16, 2020 and 25% on October 16, 2021, assuming continued employment through the applicable vesting date.
Remarks
*** Santosh's title is Senior Vice President, Chief Medical and Scientific Officer.